Barathan M, Mohamed R, Yong YK et al (2018) Viral persistence and chronicity in hepatitis C virus infection: role of T-cell apoptosis,senescence and exhaustion. Cells 7:E165. https://doi.org/10.3390/cells7100165

Article  CAS  Google Scholar 

Khadempour-Arani H, Shojaeian A, Mehri-Ghahfarrokhi A et al (2020) Identifying genotype profile of chronic hepatitis C infection in Southwest Iran. J Res Med Sci 25:85. https://doi.org/10.4103/jrms.JRMS_524_19

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aishanjiang K, Wei X, Fu Y et al (2021) Circular RNAs and hepatocellular carcinoma: new epigenetic players with diagnostic and prognostic roles. Front Oncol. https://doi.org/10.3389/fonc.2021.653717

Article  PubMed  PubMed Central  Google Scholar 

Frazzoni L, Sikandar U, Metelli F et al (2021) Hepatocellular carcinoma recurrence after hepatitis C virus therapy with direct-acting antivirals. A systematic review and meta-analysis. J Clin Med 10:1694. https://doi.org/10.3390/jcm10081694

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teng W, Liu YC, Jeng WJ, Su CW (2021) Tertiary prevention of HCC in chronic hepatitis B or C infected patients. Cancers Basel 13:1729. https://doi.org/10.3390/cancers13071729

Article  PubMed  PubMed Central  Google Scholar 

Smith DB, Bukh J, Kuiken C et al (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318–327. https://doi.org/10.1002/hep.26744

Article  PubMed  Google Scholar 

Kim CW, Chang K-M (2013) Hepatitis C virus: virology and life cycle. Clin Mol Hepatol 19:17–25. https://doi.org/10.3350/cmh.2013.19.1.17

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lohmann V, Korner F, Koch J-O et al (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110–113

Article  CAS  PubMed  Google Scholar 

Paul D, Madan V, Bartenschlager R (2014) Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe 16:569–579

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim JL, Morgenstern KA, Lin C et al (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343–355. https://doi.org/10.1016/S0092-8674(00)81351-3

Article  CAS  PubMed  Google Scholar 

Love RA, Parge HE, Wickersham JA et al (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331–342

Article  CAS  PubMed  Google Scholar 

Tran HTL, Morikawa K, Anggakusuma, et al (2020) OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. PLoS ONE 15:e0236447. https://doi.org/10.1371/journal.pone.0236447

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moradpour D, Penin F (2013) Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 369:113–142. https://doi.org/10.1007/978-3-642-27340-7_5

Article  CAS  PubMed  Google Scholar 

Jiang Y, Andrews SW, Condroski KR et al (2014) Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J Med Chem 57:1753–1769

Article  CAS  PubMed  Google Scholar 

Kwong AD, Kauffman RS, Hurter P, Mueller P (2011) Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 29:993–1003

Article  CAS  PubMed  Google Scholar 

Nageswara Rao D, Zephyr J, Henes M et al (2021) Discovery of quinoxaline-based p1–p3 macrocyclic ns3/4a protease inhibitors with potent activity against drug-resistant hepatitis C virus variants. J Med Chem 64:11972–11989. https://doi.org/10.1021/acs.jmedchem.1c00554

Article  CAS  PubMed  Google Scholar 

Neelamkavil SF, Agrawal S, Bara T et al (2016) Discovery of MK-8831, a novel spiro-proline macrocycle as a pan-genotypic HCV-NS3/4a protease inhibitor. ACS Med Chem Lett 7:111–116

Article  CAS  PubMed  Google Scholar 

Rosenquist Å, Samuelsson B, Johansson P-O et al (2014) Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem 57:1673–1693

Article  CAS  PubMed  Google Scholar 

Shah U, Jayne C, Chackalamannil S et al (2014) Novel quinoline-based P2–P4 macrocyclic derivatives as pan-genotypic HCV NS3/4a protease inhibitors. ACS Med Chem Lett 5:264–269

Article  CAS  PubMed  PubMed Central  Google Scholar 

Summa V, Ludmerer SW, McCauley JA et al (2012) MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161–4167

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gentile I, Buonomo AR, Zappulo E et al (2014) Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 10:493–504. https://doi.org/10.2147/TCRM.S66731

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCauley JA, McIntyre CJ, Rudd MT et al (2010) Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J Med Chem 53:2443–2463. https://doi.org/10.1021/jm9015526

Article  CAS  PubMed  Google Scholar 

Agarwal A, Zhang B, Olek E et al (2012) Rapid and sharp decline in HCV upon monotherapy with NS3 protease inhibitor, ACH-1625. Antivir Ther 17:1533–1539. https://doi.org/10.3851/Imp2359

Article  CAS  PubMed  Google Scholar 

Sheng XC, Appleby T, Butler T et al (2012) Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett 22:2629–2634

Article  PubMed  Google Scholar 

Li H, Scott JP, Chen C et al (2015) Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp2–sp3 Suzuki-Miyaura coupling and ring closing metathesis. Org Lett 17:1533–1536. https://doi.org/10.1021/acs.orglett.5b00418

Article  CAS  PubMed  Google Scholar 

Butt AA, Kanwal F (2012) Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 54:96–104. https://doi.org/10.1093/cid/cir774

Article  CAS  PubMed  Google Scholar 

Gentile I, Borgia F, Riccardo Buonomo A et al (2014) ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 21:3261–3270

Article  CAS  PubMed  Google Scholar 

Lawitz EJ, O’Riordan WD, Asatryan A et al (2016) Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection. Antimicrob Agents Chemother 60:1546–1555

Article  CAS  PubMed Central  Google Scholar 

Poordad F, Dieterich D (2012) Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 19:449–464. https://doi.org/10.1111/j.1365-2893.2012.01617.x

Article  CAS  PubMed  Google Scholar 

Classification of Direct-Acting Antiviral Agents in HCV Treatment Regimens. https://hepatitis.va.gov/hcv/treatment/hcv-daa-class.asp

Amoako A, Ortiz-Paredes D, Engler K et al (2021) Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. Int J Drug Policy 96:103247. https://doi.org/10.1016/j.drugpo.2021.103247

Article  PubMed  Google Scholar 

Danilescu CM, Ionescu M, Sandulescu DL et al (2022) Perceived stress in hepatitis C Virus infected patients under the DAA-based therapy. Diagnostics 12:1177. https://doi.org/10.3390/diagnostics12051177

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roger S, Ducancelle A, Le Guillou-Guillemette H et al (2021) HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 45:101626

Article  CAS  PubMed  Google Scholar 

Velazquez-Moctezuma R, Augestad EH, Castelli M et al (2021) Mechanisms of hepatitis C virus escape from vaccine-relevant neutralizing antibodies. Vaccines Basel 9:291. https://doi.org/10.3390/vaccines9030291

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin G, Lee J, Lee K (2017) Chemical genetics-based development of small molecules targeting hepatitis C virus. Arch Pharm Res 40:1021–1036. https://doi.org/10.1007/s12272-017-0949-3

Article  CAS  PubMed  Google Scholar 

Forton DM (2016) How much of a problem is resistance in treating hepatitis C? Curr Opin Infect Dis 29:625–631. https://doi.org/10.1097/QCO.0000000000000319

Article  PubMed